 |
 |
Taro granted patent for anti-tremor drug There can be no assurance, however, of the success of the clinical trials in Canada, nor that the FDA will approve the product. Adi Ben Israel 19 Oct 06 10:47 Taro Pharmaceutical Industries (Nasdaq: TARO) announced yesterday that it received a patent from the US Patent and Trademark Office for its patent application on the use its proprietary, non-sedating barbiturate compounds in the treatment of essential tremor and Parkinson's disease. The patent will expire in June 2025. It is estimated that more than six million Americans suffer from these two conditions. T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid) is Taro's first proprietary non-sedating barbiturate compound to undergo clinical testing. The drug is currently being studied for the treatment of moderate to severe essential tremor in a multi-center, randomized, double-blind, placebo-controlled trial in Canada. Taro stressed in its announcement that it could give no assurances regarding the success of its clinical trials in Canada, nor that the US Food and Drug Administration (FDA) or any foreign equivalent will approve any product, nor that any approved product will be commercially successful. Published by Globes [online], Israel business news - www.globes.co.il - on October 19, 2006 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn